This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer'

Content on this page requires a newer version of Adobe Flash Player.



Get Adobe Flash player

MOUNTAIN VIEW, Calif. (TheStreet) -- By day, Joseph Lee is a graduate student pursuing a PhD in pharmaceutical sciences and pharmacogenomics. By night, he's the "FDA Panel Whisperer" -- the creator of FDATracker.com, a unique web site that predicts outcomes of FDA advisory committees based on the historical voting records and behavioral analysis of participating panelists.

Lee has crunched the data on the 22 panel members who will sit in judgment of Vivus (VVUS) and its obesity drug Qnexa tomorrow and he's not encouraged. His prediction: 10 experts will vote to recommend Qnexa approval but the remaining 12 will vote against. That's a very close vote, made more so by Lee's acknowledgement that one or two votes could swing in either direction, according to his analysis.

Guessing the outcome of any FDA advisory panel is a big challenge; Vivus' panel is even more difficult to handicap because FDA invited eight experts who have not previously participated in any of the obesity panels held last year.

For that reason alone, I wouldn't necessarily take Lee's Vivus analysis to the bank, but his research is thorough and a compelling read if you're at all interested in following tomorrow's Qnexa presentations and the volatile deliberations that will undoubtedly follow.

Assessing the risk of birth defects caused by the topirimate component of Qnexa is likely to be the focal point of Wednesday's FDA panel debate. FDA invited Suzanne Gilboa from the National Center on Birth Defects and Development Disabilities at the CDC to present at Wednesday's panel. Her testimony could prove to be influential on the final vote.

Of the eight "new" votes on the Qnexa panel, Lee has three experts voting yes and five voting no.

Twelve experts on Wednesday's panel also participated in the last Qnexa panel. They voted 5-7 against the drug previously. This time, Lee has only one of these experts changing to a positive vote, bringing the tally in this group to a 6-6 tie.

Two additional experts invited to review Qnexa tomorrow participated in FDA panels for the two other obesity drugs last year from Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX). Lee predicts these two experts will split their votes on Qnexa.

That's how Lee comes up with his prediction for a 10-12 vote against the weight-loss drug. It's hard to get a solid read on a consensus Wall Street expectation for the Qnexa panel, but FDA's review of the drug released Friday revealed few surprises. This seems to have left investors leaning toward predicting a positive vote, although almost everyone predicts a split/close vote.

Vivus shares rose 7% Friday after the FDA release of its briefing documents but the stock was down 3% Tuesday to $11.64 per share.

I encourage you to read Lee's breakdown on how each of the panel members may vote on Qnexa based on their voting record from past obesity drug panels or statements made at other FDA panels. Tomorrow night, we'll learn if the "FDA Panel Whisperer" is accurate or not.

FDA panel members predicted to vote for Qnexa's approval, according to Lee:

Melanie Coffin, Eric Felner, Allison Goldfine, Jessica Henderson, Sanjay Kaul, Michael Rogawski, Robert Smith, Myrlene Staten, Abraham Thomas, Susan Yanovski.

FDA panel members predicted to vote against Qnexa's approval, according to Lee:

Erica Brittain, Ken Burman, David Capuzzi, Robert Clancy, Janet Cragan, Katherine Flegal, Ed Gregg, Mike Lauer, Elaine Morrato, Sonja Rasmussen, Lamont Weide, Almut Winterstein.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,051.73 -48.45 -0.28%
S&P 500 1,973.63 -4.59 -0.23%
NASDAQ 4,424.7040 -7.4420 -0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs